This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes

This study has been completed.
Merck Sharp & Dohme Corp.
Information provided by:
Bristol-Myers Squibb Identifier:
First received: October 29, 2004
Last updated: September 10, 2010
Last verified: September 2007
The purpose of this study is to learn more about how muraglitazar lowers blood sugar in people with type 2 diabetes. The safety of this treatment will also be studied.

Condition Intervention Phase
Diabetes Mellitus, Type 2 Drug: Muraglitazar Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Mechanism of Action and Efficacy of Muraglitazar (BMS298585) in the Treatment of Type 2 Diabetic Patients

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • The change from baseline in insulin medicated glucose disposal after 16 weeks of treatment with Muraglitazar

Estimated Enrollment: 42
Study Start Date: May 2004
Study Completion Date: May 2006
Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes;
  • Serum triglyceride concentration < or = 600 mg/dL;
  • Body mass index < or = 37 kg/m2

Exclusion Criteria:

  • Type 1 diabetes;
  • History of myocardial infarction (MI), coronary angioplasty, bypass graft(s), valvular disease, unstable angina pectoris, transient ischemic attack (TIA), or cerebrovascular accident (CVA) within 6 months;
  • Congestive heart failure (NYHA Class III and IV);
  • Uncontrolled hypertension;
  • Women of Child Bearing Potential
  • History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease, or endocrine disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00094991

United States, Texas
Local Institution
San Antonio, Texas, United States, 78229-3900
Local Institution
Pisa, Italy
Sponsors and Collaborators
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.
  More Information

Additional Information: Identifier: NCT00094991     History of Changes
Other Study ID Numbers: CV168-026
Study First Received: October 29, 2004
Last Updated: September 10, 2010

Keywords provided by Bristol-Myers Squibb:
Type 2 diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Glycine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on August 18, 2017